T2 Biosystems Inc (TTOO) General Counsel Sells $10,096.80 in Stock

T2 Biosystems Inc (NASDAQ:TTOO) General Counsel Michael Terrence Gibbs sold 3,005 shares of the business’s stock in a transaction on Monday, February 11th. The stock was sold at an average price of $3.36, for a total value of $10,096.80. Following the completion of the transaction, the general counsel now directly owns 60,262 shares in the company, valued at approximately $202,480.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Michael Terrence Gibbs also recently made the following trade(s):

  • On Friday, February 1st, Michael Terrence Gibbs sold 2,759 shares of T2 Biosystems stock. The stock was sold at an average price of $3.43, for a total value of $9,463.37.

Shares of NASDAQ TTOO opened at $3.45 on Wednesday. T2 Biosystems Inc has a one year low of $2.94 and a one year high of $9.98. The company has a debt-to-equity ratio of 1.66, a current ratio of 7.16 and a quick ratio of 6.81.

Several research firms have weighed in on TTOO. ValuEngine cut T2 Biosystems from a “buy” rating to a “hold” rating in a research report on Wednesday, January 2nd. Goldman Sachs Group set a $5.00 price objective on T2 Biosystems and gave the stock a “hold” rating in a research report on Friday, November 30th. Zacks Investment Research raised T2 Biosystems from a “hold” rating to a “buy” rating and set a $5.75 price objective on the stock in a research report on Thursday, November 8th. HC Wainwright set a $14.00 price target on T2 Biosystems and gave the company a “buy” rating in a research report on Friday, November 2nd. Finally, Cantor Fitzgerald set a $11.00 price target on T2 Biosystems and gave the company a “buy” rating in a research report on Friday, November 2nd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $8.94.

A number of institutional investors and hedge funds have recently modified their holdings of TTOO. Bank of New York Mellon Corp lifted its holdings in T2 Biosystems by 183.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 71,935 shares of the medical equipment provider’s stock worth $556,000 after purchasing an additional 46,567 shares in the last quarter. Schwab Charles Investment Management Inc. purchased a new stake in T2 Biosystems during the 2nd quarter worth about $444,000. BlackRock Inc. lifted its holdings in T2 Biosystems by 1,036.1% during the 2nd quarter. BlackRock Inc. now owns 1,825,811 shares of the medical equipment provider’s stock worth $14,131,000 after purchasing an additional 1,665,105 shares in the last quarter. Raymond James & Associates purchased a new stake in T2 Biosystems during the 2nd quarter worth about $100,000. Finally, Northern Trust Corp lifted its holdings in T2 Biosystems by 474.7% during the 2nd quarter. Northern Trust Corp now owns 312,079 shares of the medical equipment provider’s stock worth $2,416,000 after purchasing an additional 257,772 shares in the last quarter. 54.74% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “T2 Biosystems Inc (TTOO) General Counsel Sells $10,096.80 in Stock” was first published by Community Financial News and is owned by of Community Financial News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The original version of this news story can be viewed at https://www.com-unik.info/2019/02/13/t2-biosystems-inc-ttoo-general-counsel-sells-10096-80-in-stock.html.

About T2 Biosystems

T2 Biosystems, Inc, an in vitro diagnostics company, develops diagnostic products and product candidates in the United States. It provides T2 Magnetic Resonance platform that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, and urine.

Read More: Price to Earnings Ratio (PE) Basics

Insider Buying and Selling by Quarter for T2 Biosystems (NASDAQ:TTOO)

Receive News & Ratings for T2 Biosystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for T2 Biosystems and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit